Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF.
JAMA. 2023 Sep 19;330(11):1042-1053. doi: 10.1001/jama.2023.16503.
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM.
Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H.
Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6.
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.
Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J.
Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):165-176. doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11.
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E, Cinotti S, Morfini M, Caignoni M.
Int J Dermatol. 1990 Nov;29(9):644-8. doi: 10.1111/j.1365-4362.1990.tb02587.x.
Mannose-binding lectin-associated serine protease-1 cleaves plasminogen and plasma fibronectin: prefers plasminogen over known fibrinogen substrate.
Choudhary K, Patel PK, Are VN, Makde RD, Hajela K.
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):504-512. doi: 10.1097/MBC.0000000000001074.
A rapid screening test for reduced fibrinolytic activity of plasma: streptokinase activated lysis time.
Gidron E, Margalit R, Shalitin Y.
J Clin Pathol. 1978 Jan;31(1):54-7. doi: 10.1136/jcp.31.1.54.
Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC, Sidelmann JJ, Dolleris BB, Jørgensen JS, Johansen EKJ, Pedersen MFB, Palarasah Y, Gram JB.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221126172. doi: 10.1177/10760296221126172.
Neutrophil-Mediated Inflammatory Plasminogen Degradation, Rather Than High Plasminogen-Activator Inhibitor-1, May Underly Failures and Inefficiencies of Intrapleural Fibrinolysis.
Barrett CD, Moore PK, Moore EE, Moore HB, Chandler JG, Siddiqui H, Maginot ER, Sauaia A, Pérez-Calatayud AA, Buesing K, Wang J, Davila-Chapa C, Hershberger D, Douglas I, Pieracci FM, Yaffe MB.
Chest. 2025 Jan;167(1):67-75. doi: 10.1016/j.chest.2024.04.005. Epub 2024 May 6.
